Home  /  Resource Library  /  Polatuzumab Vedotin and Glofitamab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the Compassionate Use Program in Italy

Polatuzumab Vedotin and Glofitamab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the Compassionate Use Program in Italy

Study examined patients with DLBCL treated with polatuzumab vedotin or glofitamab in Italy